Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management

Weinberger, Vít; Bednaříková, Markéta; Cibula, David; Zikán, Michal

doi:10.1080/14737140.2016.1247699

Cited by 36 publications

(15 citation statements)

References 69 publications

(82 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Wethington et al [23] also looked at the outcome of 12 BRCA carriers diagnosed with isolated STICs and found no difference in recurrence rate after staging or no treatment. Along with other authors [23, 28, 29] they concluded that this subgroup of patients with isolated STIC diagnosed at the time of RRSO should be offered long term follow up that could include CA 125 testing, but did not comment on the extent of surveillance.…”

Section: Discussionmentioning

confidence: 98%

Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO)

et al. 2019

View full text Add to dashboard Cite

Introduction The management of Serous Tubal Intraepithelial Carcinoma (STIC) found at the time of Risk-Reducing Salpingo-Oophorectomy (RRSO) remains unclear. We set out to analyse the incidence of peritoneal carcinomas developed after prophylactic surgery and to formulate further guidance for these patients. Methods This is a retrospective study of 300 consecutive RRSO performed at the Royal Marsden Hospital between January 2008 and January 2017. Results The median age at RRSO was 47.8 years (range 34 to 60 years) and median BMI was 26.2 kg/m 2 (range 16 to 51 kg/m 2 ). A total of 273 patients (91%) were tested for BRCA mutations. Of these, 124 (45.4%) had a BRCA 1 mutation, 118 (43.2%) had a BRCA 2 mutation, 2 (0.7%) had both a BRCA 1 and a BRCA 2 mutation and 29 (10.6%) had no BRCA mutation detected. Isolated STIC lesions were identified in 7 cases (2.3%) and p53 signatures in 75 cases (25%). There were five (1.6%) incidental tubal carcinomas and one (0.3%) ovarian carcinoma at the time of surgery. Two (28.6%) of the 7 patients with STIC identified following RRSO had high grade serous peritoneal carcinoma diagnosed at 53 and 75 months. One (0.3%) patient from the other 287 patients from our series with no STIC diagnosis or incidental carcinomas at RRSO developed high grade serous carcinoma of peritoneal origin after 92 months. Conclusion This study demonstrates that when a STIC lesion is identified following RRSO there is a significantly higher risk of a subsequent peritoneal cancer. Although there is no published consensus in literature, we recommend that consideration should be given for long term follow-up if a STIC lesion is identified at RRSO.

show abstract

Section: Discussionmentioning

confidence: 98%

Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO)

et al. 2019

View full text Add to dashboard Cite

show abstract

“…The last is STIC, which is characterized by the presence of a discrete lesion, single or multiple, and located in the fimbriated end of the tube. STIC lesions display epithelial stratification and mitotic figures, demonstrating atypical histologic changes (13,19). The epithelium of STIC showed strong p53 positivity and harbors clonal TP53 mutations (12).…”

Section: Histopathology Of Precursor Lesionsmentioning

confidence: 99%

The conceptual advances of carcinogenic sequence model in high-grade serous ovarian cancer

et al. 2017

View full text Add to dashboard Cite

Abstract. The present review focuses on the current status of molecular pathology in high-grade serous cancer (HGSC) and preneoplastic conditions. This article reviews the English-language literature on HGSC, precursor, fallopian tubal epithelium, secretory cells, ciliated cells, secretory cell expansion, secretory cell outgrowth (SCOUT), p53 signature, serous tubal intraepithelial carcinoma (STIC), DNA damage and immunohistochemistry in an effort to identify the precursor-carcinoma sequence in HGSC. The majority of HGSC originates from the fimbriated end of the fallopian tube secretory epithelial cells, while the small part of this disease may develop from ovarian cortical inclusion cyst (CIC). A series of morphological changes from normal fallopian epithelium to preneoplastic to neoplastic lesions were concomitant with the multistep accumulation of molecular and genetic alterations. Recent studies provide a stepwise progression of fallopian tubal epithelium to precursor lesions to carcinoma, with the aid of a 'secretory cell-SCE-SCOUT-p53 signature-STIC-HGSC sequence' model. Immunohistochemical markers, including p53, STMN1, EZH2, CCNE1, Ki67 and γ-H2AX, were gradua lly increased during the SCOUT-p53 signature-STIC-HGSC sequence. Conversely, PAX2 expression was decreased during the early phase of SCOUT development. Potential genes and proteins are involved in the evolutionary trajectory of the precursor-cancer lineage model. In the present review we examined detailed aspects of the molecular changes involved in malignant transformation from fallopian tube epithelium to HGSC. A precursor condition originating in 'field cancerization' may gain a growth advantage, leading to HGSC.

show abstract

“…A literature review through 2016 identified 103 reported cases of isolated STIC [19], mostly found in the context of RRS for BRCA1/2 mutation. Suggested management of STIC ranges from observation to performance of surgical staging and treatment [20, 21]. In a small clinical series, positive peritoneal cytology was reported among 12% of patients with isolated STIC and cases have been described in which surgical staging prompted by detection of STIC led to identification of occult cancer (reviewed in [19]).…”

Section: Discussionmentioning

confidence: 99%

Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices

Samimi

Trabert

Duggan

et al. 2018

Gynecologic Oncology

View full text Add to dashboard Cite

show abstract

Serous tubal intraepithelial carcinoma (STIC) – clinical impact and management

Cited by 36 publications

References 69 publications

Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO)

Development of Peritoneal Carcinoma in women diagnosed with Serous Tubal Intraepithelial Carcinoma (STIC) following Risk-Reducing Salpingo-Oophorectomy (RRSO)

The conceptual advances of carcinogenic sequence model in high-grade serous ovarian cancer

Processing of fallopian tube, ovary, and endometrial surgical pathology specimens: A survey of U.S. laboratory practices

Contact Info

Product

Resources

About